Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EBITDA (2016 - 2025)

United Therapeutics (UTHR) has disclosed EBITDA for 17 consecutive years, with $356.7 million as the latest value for Q4 2025.

  • Quarterly EBITDA changed 0.28% to $356.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, up 8.39% year-over-year, with the annual reading at $1.5 billion for FY2025, 8.39% up from the prior year.
  • EBITDA hit $356.7 million in Q4 2025 for United Therapeutics, down from $388.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $388.5 million in Q3 2025 to a low of -$64.8 million in Q1 2021.
  • Historically, EBITDA has averaged $279.5 million across 5 years, with a median of $313.8 million in 2022.
  • Biggest five-year swings in EBITDA: plummeted 138.87% in 2021 and later soared 544.44% in 2022.
  • Year by year, EBITDA stood at $169.8 million in 2021, then grew by 3.42% to $175.6 million in 2022, then surged by 48.12% to $260.1 million in 2023, then soared by 37.52% to $357.7 million in 2024, then decreased by 0.28% to $356.7 million in 2025.
  • Business Quant data shows EBITDA for UTHR at $356.7 million in Q4 2025, $388.5 million in Q3 2025, and $364.5 million in Q2 2025.